

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Liraglutide for managing overweight and obesity ID740

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u> Novo Nordisk Limited (liraglutide)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • BEAT • BEMDA: Black and Ethnic Minority Diabetes Association • British Obesity Society • Cardiovascular Care Partnership • Diabetes Research and Wellness Foundation • Diabetes UK • HEART UK • Hoop UK • InDependent Diabetes Trust • Muslim Council of Britain • National Obesity Forum • Network of Sikh Organisations • Overeaters Anonymous • South Asian Health Foundation • Specialised Healthcare Alliance • Weight Concern <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for the Study of Obesity • Association of British Clinical Diabetologists • British and Irish Hypertension Society • British Association for Nursing in Cardiac Care • British Association of Endocrine and Thyroid Surgeons • British Cardiovascular Intervention Society • British Cardiovascular Society • British Dietetic Association • British Heart Foundation • British Nutrition Foundation 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Diabetes UK Cymru • Genomics England • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord UK (orlistat) • Amneal Pharma Europe (orlistat) • Cheplapharm Arzneimittel GmbH (orlistat) • GlaxoSimthKline Consumer Healthcare (orlistat) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Metabolic & Endocrine Disorders Group

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Obesity Surgery Society • British Geriatrics Society • Faculty of Public Health Medicine • National Centre for Eating Disorders • National Diabetes Nurse Consultant Group • Nurses Hypertension Association • Primary Care Diabetes Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science & Technology • Society for Endocrinology • Society for Vascular Technology • Society of Vascular Nurses • The Nutrition Society • The Obesity Management Association • TREND UK • UK Clinical Pharmacy Association • UK Health Forum • Vascular Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Dartford, Gravesham and Swanley CCG • NHS Dorset CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Cochrane Vascular • Cochrane Public Health Group • MRC Clinical Trials Unit • National Institute for Health Research • Wellcome Trust <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and social care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.